Capmatinib

Capmatinib, sold under the brand name Tabrecta, is an <a href="/facts/Anticancer_medication/fWTLbaUT">anticancer medication</a> used for the treatment of metastatic <a href="/facts/Non-small_cell_lung_cancer/9T47knRp">non-small cell lung cancer</a> whose tumors have a mutation that leads to the exon 14 skipping of the <a href="/facts/Hepatocyte_growth_factor_receptor/6QH18YEd">MET gene</a>, which codes for the membrane receptor HGFR.
The most common adverse reactions are peripheral <a href="/facts/Edema/Q6MI3KdH">edema</a>, nausea, fatigue, vomiting, <a href="/facts/Dyspnea/1jBfFzxU">dyspnea</a>, and decreased appetite.
Non-small cell lung cancer is a disease in which malignant cancer cells form in the tissues of the lung. It is the most common type of lung cancer with up to 90% of all lung carcinomas falling into the non-small cell category. Non-small cell lung cancer occurs when healthy cells become abnormal and grow rapidly. One danger of this form of cancer is that there's a high likelihood that the cancer cells will spread from the lungs to other organs and body parts. Cancer metastasis consists of a sequential series of events, and MET exon 14 skipping is recognized as a critical event for metastasis of carcinomas. Mutations leading to MET exon 14 skipping are found in 3-4% of people with lung cancer.
Capmatinib was approved for medical use in the United States in May 2020.
Capmatinib is the first therapy approved by the US <a href="/facts/Food_and_Drug_Administration/rCEnh9WB">Food and Drug Administration</a> (FDA) to treat non-small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).

Capmatinib open-in-new

Capmatinib